Articles Tagged With: levonorgestrel
-
LARC Options Expand With New Intrauterine Device
Family planning clinicians are adding another choice to the expanding list of long-acting reversible contraceptive options with the September 2016 FDA approval of the Kyleena 19.5 mg levonorgestrel IUD from Whippany, NJ-based Bayer HealthCare Pharmaceuticals. The new IUD is available as of October 2016 by prescription only.
-
Update on emergency contraception: What family planning providers need to know
Are you up to speed on emergency contraception? The Association of Reproductive Health Professionals has just released a two-part webinar to help providers review evidence-based information on all things EC, from its efficacy to the state of access in the United States.
-
Research eyes effect of body weight and BMI impact on emergency contraception
Results of a new statistical analysis of clinical data suggest a significant drop in the efficacy of levonorgestrel emergency contraceptive pills with increasing body weight.
-
Intrauterine device and implant are effective beyond use approved by the FDA
An initial analysis of data conducted by Washington University School of Medicine in St. Louis indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use.
-
Options Expand for Women: FDA Approves a New Intrauterine Device
A new option in intrauterine contraception has been approved: the LILETTA intrauterine device.
-
Data reaffirm the effectiveness of LNG, copper intrauterine devices
Findings from a recent analysis of data from a large, multi-country study of women using levonorgestrel or copper intrauterine devices (IUDs) indicate that while both forms of contraception have high levels of efficacy, the levonorgestrel device daily releasing 20 mcg was associated with a significantly lower risk of pregnancy, including ectopic pregnancy, than copper IUDs. -
Endometrial Protection: Which Progestogen Is Best?
After a lost decade, increasing numbers of women and providers are recognizing the benefits of postmenopausal hormonal therapy. For women with an intact uterus, endometrial protection is required when systemic estrogen therapy is used. Since activity at the glucocorticoid and androgen receptor may lead to adverse health effects in some women, use of pure progesterone receptor agonists may offer advantages. However, the use of natural progesterone is problematic due to low potency and poor bioavailability with oral dosing. Local therapy with the levonorgestrel intrauterine device (off-label) may be an excellent choice for many women.